

Hypersensitivity



Contact	Official email
Prof. Niveen Adel Mohamed El-wakeel	niveen10@gmail.com
Dr.Amany Elmatbouly Elsayed	amanielmatbouly@gmail.com
Dr.Aya Ahmad Elnegery	ayaelnegery@mans.edu.eg
Dr. Nada Hamid Qandeel	nadahamid@mans.edu.eg
Dr. Lamis Mohamed Taha	Lamis_mohamed@mans.edu.eg
Dr. Aya Gamal Borham	ayagamalborham@mans.edu.eg
Dr. Azza Mohamed Mamon	Azzam2010@mans.edu.eg

Learning outcomes

- By the end of this lecture the students will be able to :

- 1 • Recognize types of hypersensitivity
- 2 • Clarify the mechanism of type I hypersensitivity
- 3 • Define pharmacologically active mediators of type I hypersensitivity
- 4 • Define diagnostic tests and treatment of type I hypersensitivity.
- 5 • Compare type II, III and IV hypersensitivity
- 6 • Define the clinical types of hypersensitivity

Lecture Outline

Hypersensitivity: definition and types

- type I, mechanism, diagnosis and treatment
- Comparison of type II,III and IV Hypersensitivity
- Various clinical types of hypersensitivity

Case Scenario

Four days after birth, a female neonate with the blood type AB, Rh(D) **positive** was admitted to hospital due to **jaundice**. Her mother, 39 years old, had a normal vaginal delivery and had a history of gravida 4 para 2. The mother had no previous history of blood , plasma, or any blood products transfusions .

The newborn was apathetic and had been crying loudly when they were admitted.

The results of the seroanalysis revealed a **strong positive result (+++) on the direct Coombs test, a total bilirubin of 46.1 mg/dL, and a direct bilirubin of 1.1mg/dL.**

- State the diagnosis of this case?
- clarify the underlying mechanism?

Hypersensitivity

Definition


Hypersensitivity refers to **undesirable** (**damaging, discomfort-producing** and sometimes **fatal**) reactions produced by the normal immune system.

Hypersensitivity

Classification

Hypersensitivity reactions are classified into four types:

- type I, type II, type III (immediate reactions)
- type IV (delayed reactions)



Type I Hypersensitivity

- **Allergens:**

- ❖ **Inhalants:** Pollen grains, Fungal allergens
- ❖ **Injectants:** drugs
- ❖ **Contact:** Antiseptic spray
- ❖ **Ingestants:** egg, fish



Type I hypersensitivity immediate.


The reaction may involve:



- Skin (urticaria and eczema)
- Eyes (Conjunctivitis)
- Nasopharynx (rhinorrhea, rhinitis),
- Bronchopulmonary tissues (asthma)
- Gastrointestinal tract (gastroenteritis).

Antibody is **reactant**
Antigen is **allergen**


Signs of anaphylaxis




Rash (hives)



Dizziness, confusion




Chest tightness, difficulty breathing



Swelling of lips, tongue



Cough, wheezing



Weakness, faint pulses



Pale, sweaty, clammy



Rapid heart rate



Nausea, vomiting

The mechanism of reaction involves


Production of **IgE**, in response to certain antigens (allergens).


IgE has very high affinity for its receptor on **mast** cells and **basophils**.

A subsequent exposure to the same allergen cross links the cell-bound IgE and triggers the release of various active **substances**.

Cross-linking of allergen to IgE (binde to-Fc-receptor on mast cell) is important in mast cell **triggering**.

Mast Cell degranulation is preceded by increased **Ca⁺⁺ influx**, which is a crucial process.





Mediators of Immediate Hypersensitivity

Preformed mediators in granules:

histamine	bronchoconstriction, mucus secretion, vasodilatation, vascular permeability
Tryptase	proteolysis
ECF-A	attract eosinophil and neutrophils

Newly formed mediators:

leukotriene B4	basophil attractant
leukotriene C4, D4	same as histamine (1000x more potent)
prostaglandins	edema and pain



Diagnostic tests for immediate hypersensitivity

- **Skin** (prick and intradermal) tests.
- **Measurement of IgE antibodies** by ELISA.



Treatment



A- Avoidance of exposure.



B- Symptomatic treatment.



C- Immunotherapy


A- Avoidance of exposure.

For **dust mite** allergens: Cover mattresses and pillows with dust mite resistant covers.

For **fungus** allergens: removing indoor plants (which promote mold growth), drying or removing wet carpets.

B- Symptomatic treatment

1. **Antihistamines** which block histamine receptors.
2. **Chromolyn sodium** inhibits mast cell degranulation, by inhibiting Ca^{++} influx.



B- Symptomatic treatment

- ▶ leukotriene receptor blockers
- ▶ inhibitors of the cyclooxygenase
- ▶ **Late onset allergic symptoms**, particularly bronchoconstriction, which is mediated by leukotrienes, or short term relief from bronchoconstriction is provided by **bronchodilators** (inhalants).

C- Immunotherapy


Desensitization

- Administration of gradually **increasing** doses of allergen extracts at **regular** intervals over a period of years (starting with a very small dose), given to patients by injection, drops, or tablets under the tongue (sublingual).


Mechanism

- ▶ It is possible to teach the immune system to **tolerate** the allergen and causes the production of **'regulatory'** immune cells, which:
 - Stop the production of **IgE**
 - Rise in allergen-specific **IgG4** antibodies with blocking activity through the inhibition of allergen-induced-IgE mediated release of inflammatory mediators from mast cells.

Desensitization



Cross regulation between TH1 and TH2



Type II hypersensitivity

» 1- Incompatible blood transfusion.



- ABO: **intravascular** haemolysis (**complement**):
Manifestations: nausea, fever, rigors, back pain.

» 2- Erythroblastosis foetalis:


- RH: **extravascular** hemolysis (phagocytic cells).
- When mother (Rh **negative**) gives birth to Rh **positive** infant, at time of birth, fetal blood may enter to maternal circulation and produce **antibody** against Rh antigen.
- At **2nd birth**, the antibody will cross the placenta and become attached to Rh antigen on the surface of RBCs of the fetus and **extravascular haemolysis** occur and the infant show anemia and jaundice at first day then hepatosplenomegally and bilirubin encephalopathy.

Type II (Cytotoxic) Hypersensitivity

Antibody Dependent Cell Mediated Cytotoxicity



Antibody-dependent Cellular Cytotoxicity ADCC



Type III hypersensitivity

Arthus reaction:

- o **localized** inflammation of the small vessels (i.e., vasculitis) near the injection or bite site. immune complexes are formed around and within the blood vessels of the skin. Subsequently, activation of the **complement** cascade enhances the local **inflammation**.

- o Most individuals present with **redness, swelling, and pain**. It can also subsequently lead to induration localized to the affected area.

Serum sickness:

- o **Systemic** reaction to proteins in **antiserum** derived from **animal** source.

- o Symptoms often include a **rash, joint pain, fever, and lymphadenopathy**.

Type III Hypersensitivity - Mechanism

lumen of blood vessel

IgM or IgG antibodies

soluble antigen
(medications, insect/animal venom)

Immune Complex

Neutrophil

Granules with oxygen reactive species

C5a C3b


C1

C3b

endothelial cells lining blood vessel

- synovium of joints
- kidney glomeruli
- alveoli of the lungs

cell destruction leads to



Type IV Hypersensitivity

■ Tuberculin reaction

which peaks **48** hours after the injection of antigen (PPD or old tuberculin).

The lesion is characterized by induration and erythema.





Figure 1: Skin manifestations after 72 hours of a test performed

Mechanism

- CD4+ helper T cells recognize antigen in a complex with Class II MHC.
- CD4+ T cells secrete IL-2 and interferon gamma, further inducing the release of other **Th1** cytokines, thus mediating the immune response:
- Activated CD8+ T cells destroy target cells on contact.
- chemokines such as IL-8, monocyte chemotactic and activating factor (MCAF) that collectively lead to macrophage activation and production of hydrolytic enzymes which lead to the development of a **local** tissue reaction which is usually maximal in 48-72 h.

Type IV - Hypersensitivity

Sensitization phase




**Antigen-presenting
cells: Macrophages**

**DTH-mediating cells:
T_H1 cells generally
CD8 cells occasionally**

Overview of Hypersensitivity

Type I


IgE antibodies



- inflammation
- smooth muscle spasms

Type II


IgG/IgM antibodies



- **cytotoxic**: kill cells by complement, phagocytosis
- interfere with cell functions

Type III

IgG/IgM antibodies



immune complexes

- inflammation

Type IV

T-cells - mediated



- inflammation



Comparison between type-II, III and IV hypersensitivities:

Characteristic	Type-II	Type-III	Type-IV
Antibody	IgG, IgM	IgG, IgM	None
Antigen	Cell-bound	Soluble	Soluble or cell-bound
Response time	Minutes-hours	3-8 h.	48-72 h.

Comparison between type-II, III and IV hypersensitivities:

Characteristic	Type-II	Type-III	Type-IV
Appearance	Lysis and necrosis	Erythema and edema, necrosis	Erythema and induration
Histology	Antibody and complement	Complement and neutrophils	Monocytes, lymphocytes

Comparison between type-II, III and IV hypersensitivities:

Characteristic	Type-II	Type-III	Type-IV
immune reactant	Antibody	Antibody	T-cells
Examples	Incompatible blood transfusion, Erythroblastosis Fetalis, Autoimmune hemolytic anemia.	Arthus reaction, Serum sickness Post streptococcus glomerulonephritis RA SLE	Tuberculin test Eczema MS Type 1 DM

Case Scenario

Four days after birth, a female neonate with the blood type AB, Rh(D) **positive** was admitted to hospital due to **jaundice**. Her mother, 39 years old, had a normal vaginal delivery and had a history of gravida 4 para 2. The mother had no previous history of blood , plasma, or any blood products transfusions .

The newborn was apathetic and had been crying loudly when they were admitted.

The results of the seroanalysis revealed a **strong positive result (+++) on the direct Coombs test, a total bilirubin of 46.1 mg/dL, and a direct bilirubin of 1.1mg/dL.**

- mention the diagnosis of this case?
- clarify the underlying mechanism?




- The following is a property of IgE:

- a-Cross the placenta
- b- Dimer
- c- involved in allergic reactions
- d-Activate complement
- e- pentamer



- **Erythroblastosis fetalis** is considered :

- a. Type I hypersensitivity
- b. Type II hypersensitivity
- c. Type III hypersensitivity
- d. Type IV hypersensitivity
- e. Immunodeficiency



- Serum sickness is considered one of the types of:

- a. Type I hypersensitivity
- b. Type II hypersensitivity
- c. Type III hypersensitivity
- d. Type IV hypersensitivity
- e. Immunodeficiency

- Basic Immunology : functions and disorders of the immune system , fifth edition ; Abul K. Abbas, Andrew H. Lichtman and Shiv Pillai
- Immunology :7th edition ; David Male, Jonathan Brostoff, David Roth and Ivan Roitt

THANK

YOU

